Pharma Pool Debra BARRETT Teva Appoints New Senior VP Teva has appointed Debra Barrett as the new senior VP of global government affairs and public policy. She was previously serving in the role as senior VP of government and public affairs in the United States. Ms. Barrett has taken over the drugmaker’s global government affairs portfolio. As part of her new role, the former Senate staffer oversees a new division tasked with developing public policy for the company. Dr. Mark CURRIE Ironwood Promotes Scientific Head Ironwod Pharmaceuticals, an entrepreneurial pharmaceutical comany, has promoted Mark Currie, Ph.D., to senior VP, chief scientific officer and president of R&D. Dr. Currie has led the company’s R&D efforts since he jointed Ironwood in 2002. Biopharma Pool Elam NEVAN Dr. Sankaram MANTRIPRAGADA AntriaBio Appoints Two Industry Leaders to Its Management Team AntriaBio, a biopharmaceutical company focused on developing novel therapeutic products for the diabetes market, has appointed Nevan Elam as president and CEO, and Sankaram Mantripragada, Ph.D., as chief scientific officer. Before joining AntriaBio, Mr. Elam served as CEO of AeroSurgical Ltd., a medical device company based in Europe. Dr. Mantripragada brings to AntriaBio his strong understanding of the diabetes market and AntriaBio’s unique platform technology. He previously served as VP of R&D at PR Pharmaceuticals. CRO?Pool James TAYLOR INC Names VP James Taylor has joined INC Research as VP, clinical development. Mr. Taylor joins INC Research from Pfizer, where he served most recently as VP, global clinical trial management. In his new role, Mr. Taylor serves as the primary liaison to biopharmaceutical customers, vendors, and investigative sites for the company’s general medicine business unit. Service Pool Chris CANIZ Paul CROTTY Bill LYCETT Ken SHER Robert ZEGEL TGaS Adivsors Announces Senior-Level Hires TGaS Advisors, a benchmarking and advisory services firm for pharmaceutical commercial operations and a division of KnowledgePoint360, has hired five new senior staff members: Chris Caniz, digital and relationship marketing; Paul Crotty, Canadian operations; Bill Lycett and Ken Sher, training and development; and Robert Zegel, executive commercial operations. Mr. Caniz, service director, works with the digital and relationship marketing team to co-lead benchmarks and client advisory projects. Most recently he was with SDI/IMS Health. Mr. Crotty, VP, Canadian Operations, has been instrumental in the launch of TGaS benchmarking and advisory services to Canadian pharmaceutical. Before joining TGaS, Mr. Crotty headed his own independent consulting group. Mr. Lycett, director and management advisor for training and development, identifies performance-based needs and delivers assessment and improvement solutions for sales training executives. Before joining TGaS, Mr. Lycett consulted for pharmaceutical companies and RWD/General Physics. Mr. Sher, director and management advisor for training and development, most recently worked for Johnson & Johnson corporate as well as for several of its operating companies. Mr. Zegel, director, management advisor, manages TGaS Advisors executive commercial operations benchmarks and advisory services, helping clients realize the potential of their enterprise-wide organizations. Before coming to TGaS, Mr. Zegel worked with Pfizer for more than 20 years, most recently as senior director, US marketing. Suzanne GAGNON Idis Names Chief Medical Officer Idis has appointed Suzanne Gagnon, M.D., as chief medical officer. She also oversees global quality assurance and compliance. She was formerly chief medical officer and executive VP at ICON Clinical Research. Agency Pool Helen AN Merry LAMPI Kelly LUPTON Centron Adds to Its Team Helen An comes to Centron, a pharmaceutical advertising agency, as senior VP, associate creative director, from H4BChelsea, where she was a VP, associate creative director. Merry Lampi joins the agency as a creative supervisor, bringing with her years of experience as an art director in graphic design, digital design, and print production. Kelly Lupton joins the Centron team as a VP, account director, from LehmanMillet where she held the title of business development manager. Matthew MCCLELLAN Pinnacle Names VP Matthew McClellan has joined Pinnacle. Most recently, he led the virology payer marketing effort at Bristol-Myers Squibb, where he spearheaded access initiatives in the public payer market. Media Pool Paul SLAVIN Everyday Health Names Chief Operating Officer Everyday Health, a health and wellness media company, has promoted Paul Slavin from senior VP and general manager to chief operating officer. Biotech Pool Sean NOLAN InterMune Names Executive VP and Chief Business Officer InterMune Inc. has named Sean Nolan as executive VP and chief business officer. In this newly created position, Mr. Nolan leads the creation and establishment of InterMune’s U.S. commercial, business development and global marketing groups. He also oversees InterMune’s Canadian operations and the company’s manufacturing operations and supply chain management. Mr. Nolan joins InterMune from Reata Pharmaceuticals, where he most recently served as VP and chief commercial officer. Dr. William WESTLIN Scientific Leader to Support Nimbus Nimbus Discovery, a biotechnology company discovering novel medicines against exciting but previously inaccessible drug targets, has appointed William “Wes" Westlin, Ph.D., as head of preclinical research and early development. Dr. Westlin joins Nimbus from Celgene, where he was VP, preclinical research, following Celgene’s acquisition of Avila Therapeutics in 2012. Dr. Reed WILLIAM Cellerant Appoints VP, Clinical Development Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, has appointed William Reed, M.D. as VP, clinical development. Dr. Reed joins Cellerant from Cerus, where he served as director, clinical research and medical affairs. Biopharma Pool Dr. Michael ROGERS Chimerix Names Chief Development Officer Chimerix Inc., a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, has named Michael Rogers, Ph.D., as chief development officer. Dr. Rogers is responsible for overseeing chemistry, manufacturing, toxicology, and project management as well as the advancement of compounds from the Chimerix Chemical Library. Dr. Rogers was formerly chief development officer at Pharmasset Inc. Emerging Pool Dr. Ali FATTAEY Curis Appoints President and Chief Operating Officer Curis Inc., an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, has appointed Ali Fattaey, Ph.D., as president and chief operating officer. Dr. Fattaey joins Curis’ senior management team, where he will guide and further advance Curis’ overall corporate strategic goals and be responsible for the oversight and implementation of the company’s research and development operations. Dr. Richard OGDEN Cannabis Science appoints chief Scientific officer Cannabis Science has appointed Richard Ogden, Ph.S., as chief scientific officer. Most recently, he was director of scientific affairs, HIV, Pfizer. Dr. Ogden’s knowledge, experience and success in the discovery, development, and commercialization of new therapeutics for HIV and cancer will enhance the company’s novel clinical research and development programs on phytocannabinoid-based drugs for HIV, Kaposi’s Sarcoma (KS), and basal/squamous cell carcinomas. Agency Pool Tim PANTELLO Digitas Health Appoints Managing Director Digitas Health, a digital brand agency, has appointed Tim Pantello as managing director of its Philadelphia office. In this position, Mr. Pantello has responsibility for the Philadelphia headquarters office’s diverse client relationships and with expanding the agency’s AOR work across health and wellness brands. He joins Digitas Health from Tribal DDB, where he was the managing partner. Service Pool Mark GIANFORCARO, R.Ph. Precision Health Economics Adds Executive Sales and Marketing Leader Health economics and policy consulting company, Precision Health Economics (PHE) has hired Mark Gianforcaro, RPh, as chief marketing officer. The position supports the expansion of the PHE brand and, ultimately, the overall growth of the company. Most recently, he held executive sales and marketing positions in the i3 division of UnitedHealth Group.
